You just read:

AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan

News provided by

AbbVie

Sep 27, 2017, 00:53 ET